Terns Pharmaceuticals Inc
TERN5.750USD
+0.280+5.12%
Close 08/04, 16:00（ET）Quotes delayed by 15 min
501.96MMarket Cap
LossP/E TTM
More Details of Terns Pharmaceuticals Inc Company
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Its pipeline includes three clinical-stage development programs: TERN-701, TERN-601 and TERN-501. TERN-701 is its oral, potent, allosteric BCR-ABL tyrosine kinase inhibitors (TKI) specifically targeting the ABL myristoyl pocket for CML, a form of cancer that begins in the bone marrow and leads to the growth of leukemic cells. TERN-601 is a small-molecule glucagon-like peptide-1 receptor (GLP-1R) agonist that is intended to be orally administered for obesity and other metabolic diseases. TERN-501 is a thyroid hormone receptor beta (THR-b) agonist with high metabolic stability and liver distribution. It is also focused on developing the TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity.
Company Info
Ticker SymbolTERN
Company nameTerns Pharmaceuticals Inc
IPO dateFeb 05, 2021
CEOMs. Amy L. Burroughs
Number of employees59
Security typeOrdinary Share
Fiscal year-endFeb 05
Address1065 East Hillsdale Blvd., Suite 100
CityFOSTER CITY
Stock exchangeNASDAQ Global Select Consolidated
CountryUnited States of America
Postal code94404
Phone16505255535
Websitehttps://ternspharma.com/
Ticker SymbolTERN
IPO dateFeb 05, 2021
CEOMs. Amy L. Burroughs
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Dr. Emil T. Kuriakose, M.D.
Dr. Emil T. Kuriakose, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert W. (Bob) Azelby
Mr. Robert W. (Bob) Azelby
Independent Director
Independent Director
--
--
Ms. Amy L. Burroughs
Ms. Amy L. Burroughs
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Andrew W. Gengos
Mr. Andrew W. Gengos
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Ms. Jill M. Quigley, J.D.
Ms. Jill M. Quigley, J.D.
Independent Director
Independent Director
--
--
Dr. Radhika Tripuraneni, M.D.
Dr. Radhika Tripuraneni, M.D.
Independent Director
Independent Director
--
--
Ms. Sun (Melita) Jung
Ms. Sun (Melita) Jung
Chief Business Officer
Chief Business Officer
--
--
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
--
--
Mr. David Fellows
Mr. David Fellows
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Hongbo Lu, Ph.D.
Ms. Hongbo Lu, Ph.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Sat, May 17
Updated: Sat, May 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Soleus Capital Management, L.P.
9.35%
OrbiMed Advisors, LLC
8.66%
Vivo Capital, LLC
7.90%
Morgan Stanley & Co. LLC
7.05%
Deep Track Capital LP
6.38%
Other
60.66%
Shareholders
Shareholders
Proportion
Soleus Capital Management, L.P.
9.35%
OrbiMed Advisors, LLC
8.66%
Vivo Capital, LLC
7.90%
Morgan Stanley & Co. LLC
7.05%
Deep Track Capital LP
6.38%
Other
60.66%
Shareholder Types
Shareholders
Proportion
Hedge Fund
34.01%
Investment Advisor
22.53%
Investment Advisor/Hedge Fund
16.12%
Research Firm
9.80%
Private Equity
8.66%
Venture Capital
8.13%
Sovereign Wealth Fund
0.97%
Individual Investor
0.30%
Bank and Trust
0.13%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
343
88.10M
100.88%
-22.94M
2025Q1
352
90.67M
103.82%
-24.88M
2024Q4
339
91.95M
108.28%
-13.40M
2024Q3
310
84.11M
100.51%
-7.48M
2024Q2
277
70.14M
99.60%
-17.86M
2024Q1
253
68.60M
105.57%
-10.37M
2023Q4
237
68.12M
109.36%
-7.25M
2023Q3
218
65.97M
109.78%
-9.89M
2023Q2
209
62.15M
110.88%
-6.45M
2023Q1
187
57.73M
103.34%
-5.55M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Soleus Capital Management, L.P.
8.17M
9.35%
+24.60K
+0.30%
Mar 31, 2025
OrbiMed Advisors, LLC
7.56M
8.66%
--
--
Mar 31, 2025
Vivo Capital, LLC
6.90M
7.9%
--
--
Mar 31, 2025
Morgan Stanley & Co. LLC
6.16M
7.05%
+3.87M
+169.24%
Mar 31, 2025
Deep Track Capital LP
5.58M
6.38%
--
--
Apr 14, 2025
BlackRock Institutional Trust Company, N.A.
5.12M
5.86%
-6.44K
-0.13%
Mar 31, 2025
The Vanguard Group, Inc.
4.15M
4.75%
+282.57K
+7.30%
Mar 31, 2025
Citadel Advisors LLC
3.91M
4.47%
+640.11K
+19.59%
Mar 31, 2025
Schonfeld Strategic Advisors LLC
3.84M
4.4%
-906.64K
-19.08%
Mar 31, 2025
Candriam Luxembourg S.A.
2.88M
3.29%
+214.35K
+8.06%
May 31, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
Roundhill GLP-1 & Weight Loss ETF
2.57%
Virtus LifeSci Biotech Clinical Trials ETF
0.85%
ALPS Medical Breakthroughs ETF
0.22%
iShares Micro-Cap ETF
0.06%
ProShares Ultra Nasdaq Biotechnology
0.04%
Invesco Nasdaq Biotechnology ETF
0.04%
Avantis US Small Cap Equity ETF
0.03%
iShares Biotechnology ETF
0.03%
iShares Russell 2000 Value ETF
0.02%
Invesco RAFI US 1500 Small-Mid ETF
0.01%
View more
Roundhill GLP-1 & Weight Loss ETF
Proportion2.57%
Virtus LifeSci Biotech Clinical Trials ETF
Proportion0.85%
ALPS Medical Breakthroughs ETF
Proportion0.22%
iShares Micro-Cap ETF
Proportion0.06%
ProShares Ultra Nasdaq Biotechnology
Proportion0.04%
Invesco Nasdaq Biotechnology ETF
Proportion0.04%
Avantis US Small Cap Equity ETF
Proportion0.03%
iShares Biotechnology ETF
Proportion0.03%
iShares Russell 2000 Value ETF
Proportion0.02%
Invesco RAFI US 1500 Small-Mid ETF
Proportion0.01%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
